NCT06017973 The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus
| NCT ID | NCT06017973 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Condition | Status Epilepticus |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-10-01 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2023-10-01 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators propose a prospective study of 20 control subjects and 180 consecutive patients with possible non-convulsive status epilepticus (NCSE). The investigators will obtain three functional images of the brain: 1. Fluorodeoxyglucose positron emission tomography (FDG-PET) 2. Perfusion (and structural) magnetic resonance (MR) images 3. Computed tomography (CT) perfusion. Brain hypermetabolism/hyperperfusion is a strong argument to confirm a diagnosis of non-convulsive status epilepticus. The aim is to determine which of the three functional imaging techniques is the most sensitive and easy to obtain in the detection of hypermetabolism/hyperperfusion. The investigators will determine which EEG patterns are associated with hypermetabolism/perfusion. The investigators will further study and describe the management with antiseizure medication and outcome of the group with possible non-convulsive status epilepticus WITH hypermetabolism/hyperperfusion versus the group with possible non-convulsive status epilpticus WITHOUT hypermetabolism/hyperperfusion. The investigators will make recommendations for an imaging protocol in possible NCSE for widespread use. The aim is to offer guidelines to incorporate imaging in the diagnosis, management and prognosis of NCSE in patients with the ictal-interictal continuum.
Eligibility Criteria
Inclusion Criteria: \- The patient has possible non-convulsive status epilepticus with scalp or invasive EEG with ictal-interictal continuum patterns on EEG Exclusion Criteria: * The patient has a contra-indication for MRI such as metal implants * The patient has contrast sensitivity * The patiensuffers from claustrophobia or cannot tolerate confinement during PET-MRI scanning procedures
Contact & Investigator
Wim Van Paesschen, MD PhD
PRINCIPAL INVESTIGATOR
UZ Leuven
Frequently Asked Questions
Who can join the NCT06017973 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Status Epilepticus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06017973 currently recruiting?
Yes, NCT06017973 is actively recruiting participants. Contact the research team at Wim.vanpaesschen@kuleuven.be for enrollment information.
Where is the NCT06017973 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT06017973 clinical trial?
NCT06017973 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Wim Van Paesschen, MD PhD at UZ Leuven. The trial plans to enroll 200 participants.